A team at Penn says it has slashed CAR-T cell therapy manufacturing timeframe to just 24 hours
The future of CAR-T cell therapy research has come a long way over the years, but scientists have still been plagued by one problem: how to cut down on the timeframe, which typically takes between 9 and 14 days.
Except now. Researchers at Penn say that they have shortened the process, enhancing anti-tumor potency in just 24 hours. The preclinical study, carried out by researchers Michael Milone and Saba Ghassemi, has been published in Nature Biomedical Engineering. The results show the potential for a stark reduction of time, materials and labor that’s required to make CAR-T cells, which could be the most beneficial for those who are experiencing rapidly-progressing disease in environments with limited resources.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
